| 560.01 -5.39 (-0.95%) | 07-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 665.1  |
1-year : | 776.84 |
| Resists | First : | 569.44 |
Second : | 665.1 |
| Pivot price | 525 |
|||
| Supports | First : | 492.65 |
Second : | 445.2 |
| MAs | MA(5) : | 545.66 |
MA(20) : | 515.12 |
| MA(100) : | 494.91 |
MA(250) : | 474.44 |
|
| MACD | MACD : | 13.4 |
Signal : | 7.5 |
| %K %D | K(14,3) : | 92.4 |
D(3) : | 87.9 |
| RSI | RSI(14): 65.8  |
|||
| 52-week | High : | 615 | Low : | 286.44 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MDGL ] has closed below upper band by 3.7%. Bollinger Bands are 19.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 569.9 - 572.78 | 572.78 - 574.62 |
| Low: | 541.58 - 545.35 | 545.35 - 547.76 |
| Close: | 554.52 - 560.3 | 560.3 - 563.99 |
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Wed, 08 Jul 2026
BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL) - Insider Monkey
Wed, 08 Jul 2026
BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL) - Yahoo Finance
Tue, 07 Jul 2026
5 Best Under-the-Radar Stocks to Invest In - Insider Monkey
Mon, 06 Jul 2026
Madrigal gives seven new employees stock awards to join the company - Stock Titan
Mon, 06 Jul 2026
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mon, 06 Jul 2026
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Navigating a Promising 28.52% Upside Potential - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 106.5 (%) |
| Shares Short | 3,780 (K) |
| Shares Short P.Month | 3,900 (K) |
| EPS | -13.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 23.57 |
| Profit Margin | -27.4 % |
| Operating Margin | -29.8 % |
| Return on Assets (ttm) | -17.7 % |
| Return on Equity (ttm) | -49.4 % |
| Qtrly Rev. Growth | 126.8 % |
| Gross Profit (p.s.) | 45.53 |
| Sales Per Share | 49 |
| EBITDA (p.s.) | -13.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -268 (M) |
| Levered Free Cash Flow | -156 (M) |
| PE Ratio | -41.55 |
| PEG Ratio | 0 |
| Price to Book value | 23.74 |
| Price to Sales | 11.42 |
| Price to Cash Flow | -48.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|